These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 19553031

  • 1. Whole-pelvis radiotherapy in combination with interstitial brachytherapy: does coverage of the pelvic lymph nodes improve treatment outcome in high-risk prostate cancer?
    Bittner N, Merrick GS, Wallner KE, Butler WM, Galbreath R, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2010 Mar 15; 76(4):1078-84. PubMed ID: 19553031
    [Abstract] [Full Text] [Related]

  • 2. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E, Lief J.
    Int J Radiat Oncol Biol Phys; 2007 May 01; 68(1):34-40. PubMed ID: 17289288
    [Abstract] [Full Text] [Related]

  • 3. High-risk prostate cancer with Gleason score 8-10 and PSA level ≤15 ng/mL treated with permanent interstitial brachytherapy.
    Fang LC, Merrick GS, Butler WM, Galbreath RW, Murray BC, Reed JL, Adamovich E, Wallner KE.
    Int J Radiat Oncol Biol Phys; 2011 Nov 15; 81(4):992-6. PubMed ID: 20932674
    [Abstract] [Full Text] [Related]

  • 4. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Allen Z, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2005 Jan 01; 61(1):32-43. PubMed ID: 15629591
    [Abstract] [Full Text] [Related]

  • 5. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation.
    Vargas CE, Galalae R, Demanes J, Harsolia A, Meldolesi E, Nürnberg N, Schour L, Martinez A.
    Int J Radiat Oncol Biol Phys; 2005 Dec 01; 63(5):1474-82. PubMed ID: 15964706
    [Abstract] [Full Text] [Related]

  • 6. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL, McGrath S, Martinez AA, Vicini FA, Kestin LL.
    Int J Radiat Oncol Biol Phys; 2006 Dec 01; 66(5):1430-9. PubMed ID: 16765527
    [Abstract] [Full Text] [Related]

  • 7. Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for Gleason score 7 prostate cancer.
    Merrick GS, Galbreath RW, Butler WM, Waller KE, Allen ZA, Lief J, Adamovich E.
    Cancer; 2007 Jul 15; 110(2):289-96. PubMed ID: 17549691
    [Abstract] [Full Text] [Related]

  • 8. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ, Brandt D, Schour L, Hill DR.
    Am J Clin Oncol; 2009 Aug 15; 32(4):342-7. PubMed ID: 19398902
    [Abstract] [Full Text] [Related]

  • 9. Prostate brachytherapy in men > or =75 years of age.
    Merrick GS, Wallner KE, Galbreath RW, Butler WM, Brammer SG, Allen ZA, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2008 Oct 01; 72(2):415-20. PubMed ID: 18374514
    [Abstract] [Full Text] [Related]

  • 10. Obesity is not predictive of overall survival following permanent prostate brachytherapy.
    Merrick GS, Galbreath RW, Butler WM, Wallner KE, Allen ZA, Adamovich E.
    Am J Clin Oncol; 2007 Dec 01; 30(6):588-96. PubMed ID: 18091052
    [Abstract] [Full Text] [Related]

  • 11. Pretreatment serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy.
    Taira AV, Merrick GS, Galbreath RW, Butler WM, Wallner KE, Allen ZA, Lief JH, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2009 Jul 15; 74(4):1143-9. PubMed ID: 19117691
    [Abstract] [Full Text] [Related]

  • 12. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen Z, Lief JH, Adamovich E.
    Urology; 2005 Jan 15; 65(1):95-100. PubMed ID: 15667872
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Matched-pair analysis of prostate cancer patients with a high risk of positive pelvic lymph nodes treated with and without pelvic RT and high-dose radiation using high dose rate brachytherapy.
    Vargas CE, Demanes J, Boike TP, Barnaba MC, Skoolisariyaporn P, Schour L, Gustafson GS, Gonzalez J, Martinez AA.
    Am J Clin Oncol; 2006 Oct 15; 29(5):451-7. PubMed ID: 17023778
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
    Galalae RM, Martinez A, Mate T, Mitchell C, Edmundson G, Nuernberg N, Eulau S, Gustafson G, Gribble M, Kovács G.
    Int J Radiat Oncol Biol Phys; 2004 Mar 15; 58(4):1048-55. PubMed ID: 15001244
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Adamovich E.
    W V Med J; 2005 Mar 15; 101(4):168-71. PubMed ID: 16296198
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.